Globus Medical, Inc. (NYSE:GMED) Stock Has Consensus Price Target of $101.77 According to Analysts

Key Points

• Analysts give Globus Medical a “Moderate Buy” consensus, with nine buy ratings, three strong-buy ratings and five holds. The average 12-month price target is $101.77, above the reported share price of $74.68.
• Recent quarterly results exceeded expectations: earnings were $1.34 per share versus a $1.10 consensus estimate, while revenue rose 5.9% year over year to $789.61 million.
• Insider selling contrasts with strong institutional ownership: two directors sold shares, while institutional investors own 95.16% of the company’s stock.

Shares of Globus Medical, Inc. (NYSE:GMED - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the seventeen analysts that are presently covering the stock, Marketbeat.com reports. Five equities research analysts have rated the stock with a hold recommendation, nine have issued a buy recommendation and three have assigned a strong buy recommendation to the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is $101.77.

A number of research firms recently weighed in on GMED. Truist Financial dropped their price target on shares of Globus Medical from $115.00 to $100.00 and set a "buy" rating on the stock in a research report on Thursday, July 16th. Royal Bank Of Canada decreased their price objective on shares of Globus Medical from $120.00 to $115.00 and set an "outperform" rating for the company in a research note on Monday, July 13th. Wells Fargo & Company dropped their target price on shares of Globus Medical from $103.00 to $99.00 and set an "overweight" rating on the stock in a research report on Friday, August 7th. Weiss Ratings restated a "hold (c+)" rating on shares of Globus Medical in a research note on Monday, July 13th. Finally, BTIG Research reaffirmed a "neutral" rating on shares of Globus Medical in a research report on Friday, September 18th.

Globus Medical Stock Performance

Shares of GMED opened at $74.68 on Tuesday. Globus Medical has a 52-week low of $55.33 and a 52-week high of $101.40. The business's 50 day moving average price is $79.66 and its two-hundred day moving average price is $82.44. The firm has a market cap of $10.03 billion, a PE ratio of 19.10, a price-to-earnings-growth ratio of 1.20 and a beta of 0.95.

Globus Medical (NYSE:GMED - Get Free Report) last posted its quarterly earnings results on Thursday, August 6th. The medical device company reported $1.34 earnings per share for the quarter, beating the consensus estimate of $1.10 by $0.24. Globus Medical had a net margin of 17.02% and a return on equity of 14.57%. The firm had revenue of $789.61 million during the quarter, compared to the consensus estimate of $782.88 million. During the same period in the previous year, the firm posted $0.86 earnings per share. The business's revenue was up 5.9% compared to the same quarter last year. Globus Medical has set its FY 2026 guidance at 4.950-5.050 EPS. Research analysts predict that Globus Medical will post 4.99 EPS for the current fiscal year.

Insider Transactions at Globus Medical

In other news, Director Stephen T. Zarrilli sold 25,000 shares of the stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $87.04, for a total transaction of $2,176,000.00. Following the completion of the transaction, the director directly owned 25,000 shares of the company's stock, valued at $2,176,000. This represents a 50.00% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director James Tobin sold 30,000 shares of the firm's stock in a transaction that occurred on Tuesday, September 15th. The stock was sold at an average price of $74.58, for a total transaction of $2,237,400.00. Following the sale, the director owned 15,000 shares of the company's stock, valued at approximately $1,118,700. The trade was a 66.67% decrease in their position. The disclosure for this sale is available in the SEC filing. Company insiders own 18.38% of the company's stock.

Hedge Funds Weigh In On Globus Medical

Several institutional investors and hedge funds have recently bought and sold shares of GMED. Janus Henderson Group PLC lifted its position in shares of Globus Medical by 4.5% during the 1st quarter. Janus Henderson Group PLC now owns 7,623,095 shares of the medical device company's stock valued at $656,831,000 after buying an additional 328,217 shares during the last quarter. Sculptor Capital LP raised its stake in Globus Medical by 1.9% in the 1st quarter. Sculptor Capital LP now owns 3,058,000 shares of the medical device company's stock valued at $263,477,000 after acquiring an additional 58,000 shares during the period. Madison Avenue Partners LP raised its stake in Globus Medical by 3.0% in the 4th quarter. Madison Avenue Partners LP now owns 2,624,751 shares of the medical device company's stock valued at $229,167,000 after acquiring an additional 76,588 shares during the period. Dimensional Fund Advisors LP lifted its holdings in Globus Medical by 2.0% during the first quarter. Dimensional Fund Advisors LP now owns 1,769,897 shares of the medical device company's stock valued at $152,474,000 after purchasing an additional 33,976 shares during the last quarter. Finally, The Manufacturers Life Insurance Company lifted its holdings in Globus Medical by 2.8% during the first quarter. The Manufacturers Life Insurance Company now owns 1,132,278 shares of the medical device company's stock valued at $97,557,000 after purchasing an additional 30,412 shares during the last quarter. 95.16% of the stock is owned by institutional investors.

About Globus Medical

Globus Medical, Inc NYSE: GMED is a medical device company that develops, manufactures and markets musculoskeletal solutions for surgeons, hospitals and patients. Its primary focus is spinal surgery, supported by a portfolio of implants, instruments and enabling technologies designed to assist with procedures involving the cervical, thoracic and lumbar spine.

The company's products include spinal fusion systems, interbody devices, deformity correction systems, biologics and surgical instruments.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.